EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC 4.0

OC03 | PLASMA PACAP-38 IS INCREASED IN MIGRAINE REGARDLESS OF CLINICAL PHENOTYPE: A CASE-CONTROL STUDY

Confinia Cephalalgica · 03.11.2026 · 36 (s1)

DOI: 10.4081/cc.2026.15941 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key neuropeptide involved in migraine pathophysiology through its vasoactive, nociceptive, and neuroinflammatory effects. Although experimental evidence strongly supports its biological role, clinical studies evaluating circulating PACAP-38 concentrations have yielded inconsistent results. We aimed to compare plasma PACAP-38 concentrations between patients with migraine and healthy controls and investigate their relationship with migraine phenotype and clinical characteristics.

Methods

We conducted a single-center cross-sectional case-control study. Plasma PACAP-38 concentrations were measured using a commercially available sandwich ELISA (BlueGene Biotech; Cat. No. E01P0585). Patients were classified according to migraine phase (ictal/interictal), migraine subtype, presence of aura, medication-overuse headache (MOH), and sex. Associations with demographic and clinical variables were evaluated using non-parametric tests with correction for multiple comparisons.

Results

Eighty-five patients with migraine (70 females, 15 males; mean age 44.7 ± 14.7 years; 42 chronic and 43 episodic migraine) and 36 healthy controls (26 females, 10 males; mean age 45.3 ± 13.0 years) were included. Plasma PACAP-38 concentrations were significantly higher in patients with migraine than in healthy controls (234.86 vs 169.72 pg/mL; p

Zitieren

APA

(2026). OC03 | PLASMA PACAP-38 IS INCREASED IN MIGRAINE REGARDLESS OF CLINICAL PHENOTYPE: A CASE-CONTROL STUDY. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15941

Vancouver

OC03 | PLASMA PACAP-38 IS INCREASED IN MIGRAINE REGARDLESS OF CLINICAL PHENOTYPE: A CASE-CONTROL STUDY. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15941

BibTeX
@article{euvimed2026,
  title = {OC03 | PLASMA PACAP-38 IS INCREASED IN MIGRAINE REGARDLESS OF CLINICAL PHENOTYPE: A CASE-CONTROL STUDY},
  journal = {Confinia Cephalalgica},
  year = {2026},
  volume = {36},
  number = {s1},
  doi = {10.4081/cc.2026.15941}
}
Kostenlos starten →